Africa and Middle East Cardiovascular Epidemiological Study (ACE)
17. februar 2021 opdateret af: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region.
A total of 4300 patients will be evaluated.
In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.
Studieoversigt
Status
Afsluttet
Betingelser
Detaljeret beskrivelse
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
4386
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Alger, Algeriet, 16015
- Pfizer Investigational Site
-
Bejaja, Algeriet, 6000
- Pfizer Investigational Site
-
Djelfa, Algeriet, 17000
- Pfizer Investigational Site
-
Laghouat, Algeriet
- Pfizer Investigational Site
-
M'Sila, Algeriet
- Pfizer Investigational Site
-
Relizane, Algeriet, 48000
- Pfizer Investigational Site
-
Saida, Algeriet, 20000
- Pfizer Investigational Site
-
Tebessa, Algeriet
- Pfizer Investigational Site
-
Tlemcen, Algeriet, 13000
- Pfizer Investigational Site
-
-
-
-
-
Bafoussam, Cameroun
- Pfizer Investigational Site
-
Mbandjock, Cameroun
- Pfizer Investigational Site
-
Njombe, Cameroun
- Pfizer Investigational Site
-
Soa, Cameroun
- Pfizer Investigational Site
-
-
Cite Verte
-
Yaounde, Cite Verte, Cameroun
- Pfizer Investigational Site
-
-
Deido
-
Douala, Deido, Cameroun
- Pfizer Investigational Site
-
-
-
-
-
Alexandria, Egypten
- Pfizer Investigational Site
-
Cairo, Egypten
- Pfizer Investigational Site
-
Shiben Al Kom, Egypten
- Pfizer Investigational Site
-
Tanta, Egypten
- Pfizer Investigational Site
-
-
-
-
-
Abu Dhabi, Forenede Arabiske Emirater
- Pfizer Investigational Site
-
Al Ain, Forenede Arabiske Emirater
- Pfizer Investigational Site
-
Dubai, Forenede Arabiske Emirater
- Pfizer Investigational Site
-
Ras Al Khaima, Forenede Arabiske Emirater
- Pfizer Investigational Site
-
-
-
-
-
Accra, Ghana
- Pfizer Investigational Site
-
Jachie-Ashanti, Ghana
- Pfizer Investigational Site
-
Kumasi, Ghana
- Pfizer Investigational Site
-
Sogakope V/R, Ghana
- Pfizer Investigational Site
-
Takoradi, Ghana
- Pfizer Investigational Site
-
-
-
-
-
Amman, Jordan
- Pfizer Investigational Site
-
Irbid, Jordan
- Pfizer Investigational Site
-
Salt, Jordan
- Pfizer Investigational Site
-
-
-
-
-
Chongoria, Kenya, 60401
- Pfizer Investigational Site
-
Nairobi, Kenya, 00508
- Pfizer Investigational Site
-
-
-
-
-
Adailiya, Kuwait
- Pfizer Investigational Site
-
Fahaheel, Kuwait
- Pfizer Investigational Site
-
Kuwait, Kuwait
- Pfizer Investigational Site
-
Mishref, Kuwait
- Pfizer Investigational Site
-
Qadesya, Kuwait
- Pfizer Investigational Site
-
Yarmouk, Kuwait
- Pfizer Investigational Site
-
-
-
-
-
Beirut, Libanon
- Pfizer Investigational Site
-
Jbeil, Lebanon, Libanon
- Pfizer Investigational Site
-
Jounieh, Libanon
- Pfizer Investigational Site
-
Tripoli, Libanon
- Pfizer Investigational Site
-
-
-
-
-
Abuja, FCT, Nigeria
- Pfizer Investigational Site
-
Abuja, Garki, Nigeria
- Pfizer Investigational Site
-
Calabar, Nigeria
- Pfizer Investigational Site
-
Enugu, Nigeria
- Pfizer Investigational Site
-
Keffi, Nassarawa, Nigeria
- Pfizer Investigational Site
-
-
-
-
-
Dammam, Saudi Arabien
- Pfizer Investigational Site
-
Jeddah, Saudi Arabien
- Pfizer Investigational Site
-
Jeddah 21573, Saudi Arabien
- Pfizer Investigational Site
-
Makkah, Saudi Arabien
- Pfizer Investigational Site
-
Riyadh, Saudi Arabien
- Pfizer Investigational Site
-
Riyadh, Saudi Arabien, 11584
- Pfizer Investigational Site
-
Yanbu, Saudi Arabien
- Pfizer Investigational Site
-
-
-
-
-
Kebemer, Senegal
- Pfizer Investigational Site
-
Kedoungou, Senegal
- Pfizer Investigational Site
-
Saint Louis, Senegal
- Pfizer Investigational Site
-
Ziguinchor, Senegal
- Pfizer Investigational Site
-
-
Nabil Choucair
-
Dakar, Nabil Choucair, Senegal
- Pfizer Investigational Site
-
-
Ouakam
-
Dakar, Ouakam, Senegal
- Pfizer Investigational Site
-
-
-
-
-
Kwa-Zulu Natal, Sydafrika, 4091
- Pfizer Investigational Site
-
Rondebosch, Sydafrika, 7700
- Pfizer Investigational Site
-
-
Gauteng
-
Halfway House, Gauteng, Sydafrika, 1685
- Pfizer Investigational Site
-
-
Kwazulu-natal
-
Sydenham, Durban, Kwazulu-natal, Sydafrika, 4091
- Pfizer Investigational Site
-
-
Limpopo
-
Mokopane, Limpopo, Sydafrika, 0600
- Pfizer Investigational Site
-
Sheshego, Limpopo, Sydafrika, 0742
- Pfizer Investigational Site
-
-
Pretoria
-
Mamelodi East, Pretoria, Sydafrika, 0122
- Pfizer Investigational Site
-
-
-
-
-
Ariana, Tunesien, 2073
- Pfizer Investigational Site
-
Bouficha, Tunesien, 4010
- Pfizer Investigational Site
-
Messaadine, Tunesien, 4013
- Pfizer Investigational Site
-
Sfax, Tunesien, 3013
- Pfizer Investigational Site
-
Tunis, Tunesien, 1000
- Pfizer Investigational Site
-
Zaghouan, Tunesien, 1100
- Pfizer Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
Subject selection would be from clinics in a primary care setting
Beskrivelse
Inclusion Criteria:
- Adult aged 18 or above
Exclusion Criteria:
- Pregnant women and/or lactating mothers
- Subjects presenting with any life threatening disease/condition
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.
- Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.
- Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.
- Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2011
Primær færdiggørelse (Faktiske)
1. april 2012
Studieafslutning (Faktiske)
1. april 2012
Datoer for studieregistrering
Først indsendt
12. november 2010
Først indsendt, der opfyldte QC-kriterier
16. november 2010
Først opslået (Skøn)
18. november 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
18. februar 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. februar 2021
Sidst verificeret
1. februar 2021
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- A2581186
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .